Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Hypertension in CKD Market, by Drug Class (Diuretics, RAS Blockade, β – Blockers, Calcium Channel Blockers, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 191.8 million in 2020 and is expected to exhibit a CAGR of 10.6% during the forecast period (2020-2027).

Increasing research and development activities by the key players is expected to drive the growth of the market over the forecast period. For instance, on December 7, 2020, KBP Biosciences Holdings Limited announced positive results from its Phase 2b clinical trial of its lead candidate, KBP-5074. KBP-5074 is a non-steroidal mineralocorticoid receptor antagonist (MRA), which is being developed to treat patients suffering from chronic kidney disease and uncontrolled hypertension.

According to the Nephropharmacology journal: 2019, the following table depicts the suggested first, second, and third-line drug choices for the treatment of hypertension in CKD:

Prescribing Order Drug Class
First RAS Blockade (Angiotensin-converting-enzyme inhibitors (ACEI) or Angiotensin II receptor blockers (ARB))
Second Calcium Channel Blockers
Third Diuretics

Global Hypertension in CKD Market - Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic is expected to restrain growth of the global hypertension in CKD market over the forecast period. According to National Center for Biotechnology Information (NCBI), September 29, 2020, the treatment for chronic kidney diseases might be delayed due to the pandemic. Moreover, during the COVID-19 pandemic, the treatment of kidney disorders patients is postponed or even cancelled due to the unavailability of medications due to irregular supply and transportation of drugs.

Furthermore, according to the U.S Food and Drug Administration (FDA), September 18, 2020, the COVID-19 pandemic has disrupted the global drug supply due to government-mandated or recommended temporary shutdowns, safety initiatives to ensure employee health and well-being, insufficient labor force, and restrictions on import and export activities, and travel.

Browse 32 Market Data Tables and 25 Figures spread through 156 Pages and in-depth TOC on Global Hypertension in CKD Market, by Drug Class (Diuretics, RAS Blockade, β – Blockers, Calcium Channel Blockers, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the hypertension in CKD market, click the link below:

https://www.coherentmarketinsights.com/market-insight/hypertension-in-ckd-market-4431

Increasing prevalence of chronic kidney disease (CKD) and diabetic kidney disease (DKD), among the age groups is expected to drive the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention, (CDC), March 4, 2021, in the U.S., approximately 15% of the U.S. adults or 37 million people are currently suffering from chronic kidney disease. The following graph shows the percentage of U.S. adults in different age groups (age 18 years and above), suffering from chronic kidney disease:

Moreover, according to the National Institute of Diabetes and Digestive and Kidney Diseases: 2020, high blood glucose can damage the blood vessels in the kidneys, as many people with diabetes also develop high blood pressure. This is called as diabetic kidney disease (DKD) in type 2 diabetes. According to National Center for Biotechnology Information, (NCBI): 2017, the prevalence of DKD in most type 2 diabetics, at any point in time, is approximately 30%-50% among the U.S. diabetic adults. This prevalence was ranging between 25% in patients younger than 65 years old to nearly 50% with age older than 65 years. Therefore, patients suffering from DKD are at higher chances of suffering from hypertension.

Key Takeaways of the Hypertension in CKD Market:

  • The global hypertension in CKD market is expected to exhibit a CAGR of 10.6% over the forecast period (2020-2027), owing to rising prevalence of CKD.
  • North America accounted for major market share due to Increasing prevalence of hypertension in the end-stage kidney disease is expected to drive the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC) estimations 2019, the hypertension was observed in patients of age 65 years or above and suffering from chronic kidney disease, and according to the same source, approximately 125,000 people in the U.S. started treatment for end-stage kidney disease (ESKD) and over 726,000 (2 in every 1,000 people) in 2018 were on dialysis or had undergone kidney transplant.
  • Some of the major players operating in the global hypertension in CKD market include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner